Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neuphoria Therapeutics (NEUP) Income from Continuing Operations (2024 - 2025)

Historic Income from Continuing Operations for Neuphoria Therapeutics (NEUP) over the last 2 years, with Q4 2025 value amounting to $1.8 million.

  • Neuphoria Therapeutics' Income from Continuing Operations rose 19345.74% to $1.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$12.0 million, marking a year-over-year change of. This contributed to the annual value of -$6.6 million for FY2025, which is 5711.94% up from last year.
  • Per Neuphoria Therapeutics' latest filing, its Income from Continuing Operations stood at $1.8 million for Q4 2025, which was up 19345.74% from -$9.9 million recorded in Q3 2025.
  • In the past 5 years, Neuphoria Therapeutics' Income from Continuing Operations registered a high of $11.3 million during Q1 2025, and its lowest value of -$15.2 million during Q2 2025.